Ariela R Orkaby1,2,3, Luc Djousse2,3, JoAnn E Manson4,5. 1. New England GRECC (Geriatric Research, Education, and Clinical Center), VA Boston Healthcare System. 2. Division of Aging, Brigham and Women's Hospital, Harvard Medical School. 3. Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System. 4. Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School. 5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: The role of vitamin D supplementation for prevention of cardiovascular disease (CVD) outcomes has been rigorously studied only recently. This review briefly summarizes results from recent randomized controlled trials in the context of prior laboratory and epidemiologic data. RECENT FINDINGS: Randomized trials of vitamin D that included CVD outcomes, as well as two recently published large population-based trials that prespecified CVD as a primary endpoint (The Vitamin D Assessmentand The VITamin D and OmegA-3 TriaL), indicate that vitamin D supplementation does not decrease CVD incidence, when compared with placebo. SUMMARY: Evidence to date suggests that vitamin D supplementation in the general community does not reduce the risk of major cardiovascular events. Other trials are ongoing and future studies will explore additional CVD outcomes such as heart failure and assess high-risk populations such as those with chronic kidney disease.
PURPOSE OF REVIEW: The role of vitamin D supplementation for prevention of cardiovascular disease (CVD) outcomes has been rigorously studied only recently. This review briefly summarizes results from recent randomized controlled trials in the context of prior laboratory and epidemiologic data. RECENT FINDINGS: Randomized trials of vitamin D that included CVD outcomes, as well as two recently published large population-based trials that prespecified CVD as a primary endpoint (The Vitamin D Assessmentand The VITamin D and OmegA-3 TriaL), indicate that vitamin D supplementation does not decrease CVD incidence, when compared with placebo. SUMMARY: Evidence to date suggests that vitamin D supplementation in the general community does not reduce the risk of major cardiovascular events. Other trials are ongoing and future studies will explore additional CVD outcomes such as heart failure and assess high-risk populations such as those with chronic kidney disease.
Authors: A M Grant; A Avenell; M K Campbell; A M McDonald; G S MacLennan; G C McPherson; F H Anderson; C Cooper; R M Francis; C Donaldson; W J Gillespie; C M Robinson; D J Torgerson; W A Wallace Journal: Lancet Date: 2005 May 7-13 Impact factor: 79.321
Authors: Judith Hsia; Gerardo Heiss; Hong Ren; Matthew Allison; Nancy C Dolan; Philip Greenland; Susan R Heckbert; Karen C Johnson; JoAnn E Manson; Stephen Sidney; Maurizio Trevisan Journal: Circulation Date: 2007-02-20 Impact factor: 29.690